 Nalu Navarro Alvarez
Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatocytes | 22 | 2016 | 224 | 2.340 |
Why?
| | Liver Transplantation | 13 | 2023 | 823 | 2.290 |
Why?
| | Transplantation, Heterologous | 13 | 2020 | 194 | 2.110 |
Why?
| | Acute-On-Chronic Liver Failure | 4 | 2023 | 5 | 1.830 |
Why?
| | Liver Diseases | 7 | 2022 | 304 | 1.530 |
Why?
| | Liver Regeneration | 7 | 2022 | 46 | 1.300 |
Why?
| | Liver Failure | 5 | 2018 | 83 | 1.070 |
Why?
| | Graft Rejection | 5 | 2020 | 540 | 1.070 |
Why?
| | Swine | 15 | 2018 | 833 | 0.950 |
Why?
| | Galectins | 2 | 2022 | 27 | 0.890 |
Why?
| | Embryonic Stem Cells | 8 | 2009 | 130 | 0.890 |
Why?
| | Galectin 3 | 3 | 2022 | 21 | 0.850 |
Why?
| | CD47 Antigen | 3 | 2016 | 42 | 0.830 |
Why?
| | Papio | 6 | 2018 | 85 | 0.800 |
Why?
| | Blood Coagulation Factors | 5 | 2020 | 55 | 0.800 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 16 | 0.730 |
Why?
| | Heterografts | 2 | 2020 | 144 | 0.730 |
Why?
| | Cell Culture Techniques | 9 | 2009 | 375 | 0.670 |
Why?
| | Blood Component Removal | 2 | 2018 | 28 | 0.660 |
Why?
| | Tissue Engineering | 8 | 2022 | 442 | 0.650 |
Why?
| | Graft Survival | 8 | 2020 | 526 | 0.650 |
Why?
| | Models, Animal | 3 | 2020 | 392 | 0.570 |
Why?
| | Islets of Langerhans Transplantation | 4 | 2008 | 67 | 0.550 |
Why?
| | Liver | 13 | 2022 | 1888 | 0.530 |
Why?
| | Liver Cirrhosis | 5 | 2023 | 288 | 0.530 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.520 |
Why?
| | Bone Marrow Transplantation | 2 | 2015 | 294 | 0.480 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 5 | 0.470 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.450 |
Why?
| | Animals | 50 | 2022 | 38109 | 0.450 |
Why?
| | Thrombocytopenia | 2 | 2016 | 205 | 0.430 |
Why?
| | Immunity, Humoral | 1 | 2015 | 120 | 0.430 |
Why?
| | Stem Cells | 4 | 2016 | 627 | 0.410 |
Why?
| | Inflammation | 3 | 2022 | 2880 | 0.400 |
Why?
| | Gene Deletion | 2 | 2013 | 389 | 0.390 |
Why?
| | Prognosis | 4 | 2022 | 4293 | 0.390 |
Why?
| | Swine, Miniature | 3 | 2018 | 89 | 0.380 |
Why?
| | Peptides | 3 | 2010 | 998 | 0.380 |
Why?
| | Islets of Langerhans | 5 | 2008 | 833 | 0.370 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.350 |
Why?
| | Liver Failure, Acute | 6 | 2015 | 67 | 0.350 |
Why?
| | Bone Marrow Cells | 2 | 2010 | 320 | 0.340 |
Why?
| | Cell Differentiation | 11 | 2010 | 2050 | 0.330 |
Why?
| | Hemorrhage | 1 | 2016 | 809 | 0.320 |
Why?
| | Blood Proteins | 2 | 2022 | 249 | 0.310 |
Why?
| | B-Lymphocytes | 1 | 2015 | 877 | 0.310 |
Why?
| | Animals, Genetically Modified | 4 | 2018 | 250 | 0.300 |
Why?
| | Biomarkers | 6 | 2022 | 4275 | 0.300 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2008 | 198 | 0.300 |
Why?
| | Cell Separation | 1 | 2010 | 307 | 0.300 |
Why?
| | Hepatectomy | 6 | 2018 | 273 | 0.290 |
Why?
| | Phagocytosis | 1 | 2011 | 299 | 0.290 |
Why?
| | Tissue Scaffolds | 2 | 2009 | 223 | 0.290 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 286 | 0.280 |
Why?
| | Glycoproteins | 1 | 2010 | 355 | 0.280 |
Why?
| | Colonic Neoplasms | 1 | 2010 | 260 | 0.270 |
Why?
| | Cell Transplantation | 4 | 2010 | 39 | 0.260 |
Why?
| | Fibronectins | 1 | 2008 | 136 | 0.260 |
Why?
| | Antigens, CD | 1 | 2010 | 555 | 0.250 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 84 | 0.250 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 96 | 0.250 |
Why?
| | Humans | 43 | 2023 | 144957 | 0.250 |
Why?
| | Cytokines | 3 | 2022 | 2065 | 0.250 |
Why?
| | Fibroblast Growth Factor 2 | 6 | 2009 | 93 | 0.230 |
Why?
| | Liver, Artificial | 4 | 2010 | 5 | 0.230 |
Why?
| | Transplantation, Heterotopic | 2 | 2018 | 16 | 0.220 |
Why?
| | Mice | 23 | 2016 | 18365 | 0.220 |
Why?
| | Hepatocyte Growth Factor | 5 | 2008 | 33 | 0.210 |
Why?
| | Mice, SCID | 8 | 2010 | 369 | 0.210 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 3550 | 0.190 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.180 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 104 | 0.170 |
Why?
| | Pancreas, Artificial | 3 | 2009 | 97 | 0.170 |
Why?
| | Liver Function Tests | 2 | 2020 | 106 | 0.170 |
Why?
| | Consensus | 1 | 2023 | 489 | 0.170 |
Why?
| | Inflammation Mediators | 2 | 2022 | 509 | 0.170 |
Why?
| | Stem Cell Transplantation | 4 | 2009 | 191 | 0.170 |
Why?
| | Gastroenterology | 1 | 2023 | 189 | 0.160 |
Why?
| | Choledocholithiasis | 1 | 2020 | 20 | 0.160 |
Why?
| | Gallstones | 1 | 2020 | 35 | 0.150 |
Why?
| | Lithotripsy | 1 | 2020 | 49 | 0.150 |
Why?
| | Brain Diseases | 1 | 2020 | 153 | 0.150 |
Why?
| | Risk | 1 | 2022 | 911 | 0.150 |
Why?
| | End Stage Liver Disease | 1 | 2020 | 94 | 0.150 |
Why?
| | Galactosyltransferases | 1 | 2018 | 12 | 0.150 |
Why?
| | Primates | 1 | 2020 | 132 | 0.140 |
Why?
| | Renal Insufficiency | 1 | 2020 | 169 | 0.140 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 116 | 0.140 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 18 | 0.140 |
Why?
| | Lithiasis | 1 | 2017 | 3 | 0.140 |
Why?
| | Postoperative Complications | 3 | 2022 | 2920 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 224 | 0.130 |
Why?
| | Cell Line | 6 | 2010 | 2882 | 0.130 |
Why?
| | Postoperative Care | 1 | 2020 | 288 | 0.130 |
Why?
| | Retrospective Studies | 5 | 2022 | 17101 | 0.130 |
Why?
| | Neovascularization, Physiologic | 3 | 2009 | 194 | 0.130 |
Why?
| | Ammonia | 6 | 2007 | 65 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2013 | 4155 | 0.130 |
Why?
| | Preoperative Care | 1 | 2020 | 380 | 0.130 |
Why?
| | Mycoplasma ovipneumoniae | 1 | 2016 | 2 | 0.120 |
Why?
| | Peptide Elongation Factor Tu | 1 | 2016 | 5 | 0.120 |
Why?
| | Lymphocyte Depletion | 1 | 2016 | 132 | 0.120 |
Why?
| | Endoscopy, Digestive System | 1 | 2017 | 140 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2118 | 0.120 |
Why?
| | Transplantation Tolerance | 1 | 2016 | 37 | 0.120 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2016 | 76 | 0.120 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2009 | 157 | 0.120 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2016 | 55 | 0.120 |
Why?
| | Antibodies, Heterophile | 1 | 2015 | 13 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2018 | 4569 | 0.110 |
Why?
| | Lidocaine | 5 | 2006 | 54 | 0.110 |
Why?
| | Albumins | 5 | 2007 | 118 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 847 | 0.110 |
Why?
| | Health Status Indicators | 1 | 2016 | 166 | 0.110 |
Why?
| | alpha-Fetoproteins | 1 | 2015 | 40 | 0.110 |
Why?
| | Neoplastic Stem Cells | 2 | 2010 | 412 | 0.110 |
Why?
| | Activins | 4 | 2008 | 29 | 0.110 |
Why?
| | Treatment Outcome | 7 | 2020 | 11695 | 0.110 |
Why?
| | Oligopeptides | 2 | 2007 | 269 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2925 | 0.100 |
Why?
| | Mice, Inbred BALB C | 7 | 2016 | 1253 | 0.100 |
Why?
| | Exosomes | 1 | 2015 | 104 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 389 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 104 | 0.100 |
Why?
| | Macrophage-1 Antigen | 1 | 2013 | 26 | 0.100 |
Why?
| | Nanofibers | 2 | 2010 | 24 | 0.100 |
Why?
| | Coculture Techniques | 3 | 2010 | 246 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2015 | 379 | 0.100 |
Why?
| | Skin | 1 | 2018 | 758 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2008 | 3890 | 0.090 |
Why?
| | Female | 14 | 2022 | 78376 | 0.090 |
Why?
| | Cell Proliferation | 3 | 2010 | 2499 | 0.090 |
Why?
| | Apoptosis | 4 | 2010 | 2430 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 148 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2016 | 456 | 0.090 |
Why?
| | Microscopy, Electron, Scanning | 3 | 2006 | 199 | 0.090 |
Why?
| | Embryonic Induction | 2 | 2008 | 31 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2010 | 381 | 0.080 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 372 | 0.080 |
Why?
| | Gelatin | 2 | 2009 | 56 | 0.080 |
Why?
| | AC133 Antigen | 1 | 2010 | 20 | 0.080 |
Why?
| | Immunity, Innate | 2 | 2015 | 846 | 0.080 |
Why?
| | Time Factors | 4 | 2010 | 7183 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 81 | 0.080 |
Why?
| | Alkaline Phosphatase | 2 | 2008 | 145 | 0.080 |
Why?
| | Polytetrafluoroethylene | 2 | 2007 | 25 | 0.080 |
Why?
| | Cell Line, Transformed | 2 | 2007 | 140 | 0.080 |
Why?
| | Stromal Cells | 1 | 2010 | 125 | 0.080 |
Why?
| | Injections, Intramuscular | 1 | 2009 | 141 | 0.070 |
Why?
| | Prospective Studies | 1 | 2022 | 7997 | 0.070 |
Why?
| | Insulin | 4 | 2008 | 2507 | 0.070 |
Why?
| | Male | 11 | 2022 | 72406 | 0.070 |
Why?
| | Adult | 5 | 2022 | 40506 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2016 | 5997 | 0.070 |
Why?
| | Nanotechnology | 1 | 2009 | 126 | 0.070 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2009 | 80 | 0.070 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 675 | 0.070 |
Why?
| | Organoids | 1 | 2010 | 141 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 701 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2015 | 783 | 0.070 |
Why?
| | Endoderm | 1 | 2008 | 21 | 0.070 |
Why?
| | Nanog Homeobox Protein | 1 | 2008 | 14 | 0.070 |
Why?
| | Culture Media, Serum-Free | 1 | 2008 | 42 | 0.070 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2008 | 19 | 0.070 |
Why?
| | Drug Discovery | 1 | 2009 | 155 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2010 | 1786 | 0.070 |
Why?
| | Abdomen | 1 | 2009 | 141 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1982 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 111 | 0.070 |
Why?
| | Japan | 1 | 2008 | 143 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2185 | 0.070 |
Why?
| | Middle Aged | 5 | 2022 | 35928 | 0.060 |
Why?
| | Phenotype | 3 | 2010 | 3164 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 930 | 0.060 |
Why?
| | Survival Rate | 3 | 2020 | 2092 | 0.060 |
Why?
| | Polyurethanes | 1 | 2007 | 38 | 0.060 |
Why?
| | Organ Preservation | 1 | 2008 | 130 | 0.060 |
Why?
| | Survival Analysis | 4 | 2016 | 1385 | 0.060 |
Why?
| | Bioartificial Organs | 1 | 2006 | 3 | 0.060 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 188 | 0.060 |
Why?
| | Rats | 5 | 2017 | 5614 | 0.060 |
Why?
| | Membranes, Artificial | 1 | 2006 | 75 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1048 | 0.060 |
Why?
| | Genetic Enhancement | 1 | 2005 | 5 | 0.060 |
Why?
| | Bone Substitutes | 1 | 2006 | 26 | 0.060 |
Why?
| | Bone Regeneration | 1 | 2006 | 28 | 0.060 |
Why?
| | Pancreas | 1 | 2008 | 342 | 0.060 |
Why?
| | Totipotent Stem Cells | 1 | 2005 | 1 | 0.060 |
Why?
| | Bone Transplantation | 1 | 2006 | 87 | 0.060 |
Why?
| | Glucose | 2 | 2008 | 1049 | 0.060 |
Why?
| | Delayed-Action Preparations | 1 | 2006 | 183 | 0.050 |
Why?
| | Nanostructures | 1 | 2006 | 117 | 0.050 |
Why?
| | Skull | 1 | 2006 | 158 | 0.050 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 586 | 0.050 |
Why?
| | Aged | 2 | 2022 | 25947 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2008 | 699 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 524 | 0.050 |
Why?
| | Gene Transfer Techniques | 1 | 2005 | 185 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 456 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2010 | 1322 | 0.050 |
Why?
| | Mexico | 1 | 2023 | 233 | 0.050 |
Why?
| | Knowledge | 1 | 2022 | 57 | 0.050 |
Why?
| | Pregnancy | 1 | 2015 | 7191 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 174 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 2017 | 893 | 0.050 |
Why?
| | Diazepam | 3 | 2007 | 33 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2006 | 553 | 0.040 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 1098 | 0.040 |
Why?
| | Cell Survival | 3 | 2010 | 1098 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 1034 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2006 | 870 | 0.040 |
Why?
| | Muscle, Skeletal | 1 | 2009 | 1796 | 0.040 |
Why?
| | Sus scrofa | 2 | 2010 | 64 | 0.040 |
Why?
| | Adult Stem Cells | 2 | 2008 | 39 | 0.030 |
Why?
| | Gene Expression | 3 | 2008 | 1490 | 0.030 |
Why?
| | Endoscopy | 1 | 2020 | 316 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1325 | 0.030 |
Why?
| | Receptors, CCR4 | 1 | 2016 | 23 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2017 | 60 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 181 | 0.030 |
Why?
| | Cross Reactions | 1 | 2016 | 130 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2016 | 65 | 0.030 |
Why?
| | Immunotoxins | 1 | 2016 | 55 | 0.030 |
Why?
| | Interleukin-5 | 1 | 2016 | 39 | 0.030 |
Why?
| | Endothelial Progenitor Cells | 1 | 2016 | 20 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 983 | 0.030 |
Why?
| | Spleen | 2 | 2010 | 508 | 0.030 |
Why?
| | Interleukin-12 | 1 | 2016 | 117 | 0.030 |
Why?
| | Blood Vessels | 2 | 2009 | 171 | 0.030 |
Why?
| | Skin Transplantation | 1 | 2016 | 85 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2016 | 206 | 0.030 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2016 | 72 | 0.030 |
Why?
| | Diagnosis | 1 | 2015 | 16 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2016 | 272 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 631 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 851 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 268 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 697 | 0.030 |
Why?
| | Cell Division | 2 | 2006 | 766 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1371 | 0.020 |
Why?
| | Actins | 2 | 2006 | 425 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2016 | 784 | 0.020 |
Why?
| | ROC Curve | 1 | 2015 | 615 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 420 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2016 | 780 | 0.020 |
Why?
| | Neoplasms | 1 | 2008 | 2884 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1217 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2014 | 405 | 0.020 |
Why?
| | Implants, Experimental | 1 | 2010 | 21 | 0.020 |
Why?
| | Bioengineering | 1 | 2010 | 20 | 0.020 |
Why?
| | Hospitalization | 1 | 2020 | 2434 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2016 | 1167 | 0.020 |
Why?
| | Endotoxemia | 1 | 2010 | 87 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1524 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2010 | 2609 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2009 | 103 | 0.020 |
Why?
| | Glucocorticoid-Induced TNFR-Related Protein | 1 | 2008 | 5 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3125 | 0.020 |
Why?
| | Regeneration | 1 | 2010 | 197 | 0.020 |
Why?
| | Fetal Stem Cells | 1 | 2008 | 8 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2008 | 415 | 0.020 |
Why?
| | Carbon Tetrachloride | 1 | 2008 | 13 | 0.020 |
Why?
| | Biomedical Engineering | 1 | 2008 | 29 | 0.020 |
Why?
| | Hepatic Artery | 1 | 2008 | 53 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 376 | 0.020 |
Why?
| | Regenerative Medicine | 1 | 2008 | 50 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2007 | 17 | 0.020 |
Why?
| | Annexin A5 | 1 | 2007 | 21 | 0.020 |
Why?
| | Transcription Factors | 2 | 2006 | 1742 | 0.020 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 9 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 354 | 0.020 |
Why?
| | Retroviridae | 1 | 2007 | 101 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 610 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 863 | 0.020 |
Why?
| | Portal Vein | 1 | 2008 | 114 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 662 | 0.020 |
Why?
| | Dexamethasone | 1 | 2008 | 372 | 0.020 |
Why?
| | Integrases | 1 | 2007 | 122 | 0.010 |
Why?
| | Sp7 Transcription Factor | 1 | 2006 | 7 | 0.010 |
Why?
| | Tissue Survival | 1 | 2006 | 16 | 0.010 |
Why?
| | Tamoxifen | 1 | 2007 | 217 | 0.010 |
Why?
| | Haplorhini | 1 | 2006 | 52 | 0.010 |
Why?
| | Risk Factors | 1 | 2020 | 10792 | 0.010 |
Why?
| | Glycogen | 1 | 2006 | 54 | 0.010 |
Why?
| | Ganciclovir | 1 | 2006 | 53 | 0.010 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2006 | 45 | 0.010 |
Why?
| | Urethane | 1 | 2006 | 43 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2007 | 205 | 0.010 |
Why?
| | Polyamines | 1 | 2006 | 42 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2006 | 70 | 0.010 |
Why?
| | Textiles | 1 | 2006 | 22 | 0.010 |
Why?
| | Blood Glucose | 2 | 2006 | 2330 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 241 | 0.010 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2005 | 15 | 0.010 |
Why?
| | Urea | 1 | 2006 | 84 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2005 | 17 | 0.010 |
Why?
| | Coated Materials, Biocompatible | 1 | 2006 | 65 | 0.010 |
Why?
| | Serum Albumin | 1 | 2006 | 147 | 0.010 |
Why?
| | Tissue Culture Techniques | 1 | 2005 | 83 | 0.010 |
Why?
| | Collagen Type I | 1 | 2006 | 147 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 232 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2540 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2006 | 361 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2006 | 455 | 0.010 |
Why?
| | Tissue Donors | 1 | 2007 | 424 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2005 | 337 | 0.010 |
Why?
| | Laparoscopy | 1 | 2008 | 475 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2005 | 346 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1718 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2032 | 0.010 |
Why?
| | Genetic Variation | 1 | 2005 | 984 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1822 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1500 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2832 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 4099 | 0.010 |
Why?
| | Child | 1 | 2005 | 22657 | 0.000 |
Why?
|
|
Navarro Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|